Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide

[1]  J. Adamski,et al.  Integrated view on 17beta-hydroxysteroid dehydrogenases , 2009, Molecular and Cellular Endocrinology.

[2]  H. Handa,et al.  17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. , 2009, Cancer research.

[3]  W. Leitner,et al.  Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. , 2009, Blood.

[4]  J. Wolchok,et al.  Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. , 2008, Cancer research.

[5]  D. Rickman,et al.  Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays , 2008, Oncogene.

[6]  Peter M. Schlag,et al.  Novel Jet-Injection Technology for Nonviral Intratumoral Gene Transfer in Patients with Melanoma and Breast Cancer , 2008, Clinical Cancer Research.

[7]  T. Whiteside,et al.  Development of multi-epitope vaccines targeting wild-typesequence p53 peptides , 2008, Expert review of vaccines.

[8]  R. Draghia‐Akli,et al.  DNA vaccination and gene therapy: optimization and delivery for cancer therapy , 2008, Expert review of vaccines.

[9]  J. Kirkwood,et al.  Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Rammensee,et al.  Plasmid DNA- and messenger RNA-based anti-cancer vaccination. , 2008, Immunology letters.

[11]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[12]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[13]  Hailing Lu,et al.  The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. , 2006, Cancer research.

[14]  F. Labrie,et al.  Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. , 2006, Molecular endocrinology.

[15]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[16]  E. Nakayama,et al.  Murine leukemia RL1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL) , 2003, Cancer science.

[17]  Antoni Ribas,et al.  Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Miyazaki,et al.  A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells , 2002, Cancer Gene Therapy.

[19]  P. Srivastava,et al.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[21]  Santa Jeremy Ono,et al.  CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice1 , 2000, The Journal of Immunology.

[22]  P. Arlotta,et al.  CD4 T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice , 2000 .

[23]  V. Cerundolo,et al.  Effect of epitope flanking residues on the presentation of N‐terminal cytotoxic T lymphocyte epitopes , 1999, European journal of immunology.

[24]  P. Robbins,et al.  Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen , 1999, Gene Therapy.

[25]  C. Uyttenhove,et al.  Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. , 1999, Journal of immunology.

[26]  M. Lotze,et al.  Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice , 1999, Cancer Gene Therapy.

[27]  N. Yang,et al.  Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. , 1997, Human gene therapy.

[28]  J. Shabanowitz,et al.  The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68 , 1997, The Journal of experimental medicine.

[29]  C. Ho,et al.  Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. , 1996, Journal of immunology.

[30]  E. Jaffee,et al.  Murine tumor antigens: is it worth the search? , 1996, Current opinion in immunology.

[31]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[32]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[33]  J. Shabanowitz,et al.  Use of tandem mass spectrometry for MHC ligand analysis , 1996 .

[34]  A. Agulnik,et al.  Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. , 1995, Science.

[35]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Mayordomo,et al.  Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. , 1995, Cancer Research.

[37]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[38]  L. Old,et al.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[40]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[41]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[42]  J R Yates,et al.  Protein sequencing by tandem mass spectrometry. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Rosenberg,et al.  In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. , 1986, Journal of immunology.

[44]  L. Old,et al.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.

[45]  L. Old,et al.  ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .

[46]  L. Gross.  Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line , 1943 .